Sh Pharma announced that its wholly-owned subsidiary Shangyao Xinyi has received the approval notice for clinical trials of WST03 preparation from the National Medical Products Administration, and will soon initiate domestic Phase I clinical trials.
上海医药：WST03制剂获临床试验批准
Sh Pharma: Clinical trial approval for WST03 formulation.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.